Bioactive macrocyclic inhibitors of the PD-1/PD-L1 immune checkpoint

Blockade of the immunoinhibitory PD-1/PD-L1 pathway using monoclonal antibodies has shown impressive results with durable clinical antitumor responses. Anti-PD-1 and anti-PD-L1 antibodies have now been approved for the treatment of a number of tumor types whereas the development of small molecules t...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Angew Chem Int Ed Engl
Main Authors: Magiera-Mularz, Katarzyna, Skalniak, Lukasz, Zak, Krzysztof M., Musielak, Bogdan, Rudzinska-Szostak, Ewa, Berlicki, Łukasz, Kocik, Justyna, Grudnik, Przemyslaw, Sala, Dominik, Zizigas-Zarganis, Tryfonas, Shaabani, Shabnam, Dömling, Alexander, Dubin, Grzegorz, Holak, Tad A.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6400216/
https://ncbi.nlm.nih.gov/pubmed/28881104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/anie.201707707
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki